AI Oncology Software: Features & Development Guide

A medical oncologist opens the chart of a newly diagnosed patient with stage III colon cancer. The information she needs is scattered across the record: a pathology report in one system, genomic sequencing results in a PDF from an outside laboratory, imaging reports in the radiology system, a family history buried in a nursing note, and three prior treatment summaries from another hospital. She has twenty minutes before the patient arrives.

She must determine the stage, confirm biomarker status, check guideline-concordant treatment options, screen for clinical trial eligibility, and anticipate drug interactions with the patient's existing heart medications. Each task is a research project on its own. The patient's tumor board is on Thursday, and the coordinator is still chasing missing records.

Cancer care is among the most data-intensive and time-sensitive fields in medicine. Treatment decisions depend on dozens of variables that must be gathered, interpreted, and matched against guidelines and evidence that change monthly. Delays of weeks between diagnosis and treatment measurably affect outcomes, yet the administrative and informational burden that causes those delays continues to grow.

AI oncology software addresses this directly. It assembles a unified patient picture from fragmented records, supports guideline-concordant treatment planning, matches patients to clinical trials, streamlines tumor board preparation, and monitors patients through treatment. It does not replace the oncologist's judgment. It gives her the organized, current information that judgment requires.

In 2026, AI oncology platforms are transforming care across cancer centers, community oncology practices, hospital systems, and health tech companies. The organizations deploying them effectively are reducing time to treatment, improving trial enrollment, and giving oncology teams time back for patients.

Key Takeaways

AI oncology software uses machine learning, NLP, and clinical decision support to unify patient data, extract structured information from pathology and genomic reports, support guideline-concordant treatment planning, match patients to clinical trials, prepare tumor boards, and monitor patients during treatment
Cancer is the second leading cause of death in the US, with roughly two million new diagnoses each year, and treatment is increasingly personalized by biomarkers and genomics, which multiplies the information oncologists must synthesize
The highest-value AI capabilities are NLP extraction from unstructured oncology documents, clinical trial matching, treatment guideline support, tumor board workflow automation, symptom and toxicity monitoring, and oncology practice analytics
Fewer than 5 percent of adult cancer patients enroll in clinical trials, and eligibility screening burden is a major barrier, making AI trial matching one of the highest-impact applications
HIPAA compliance is required, and genomic data adds sensitivity because it can identify individuals and reveal information about relatives, so enhanced protections and GINA considerations apply
FDA regulatory classification applies to AI that recommends specific treatments or analyzes pathology and imaging for diagnostic purposes, while tools that organize information and support workflow often qualify for clinical decision support exemptions
Total development cost ranges from $60,000 for a focused data abstraction MVP to $520,000 or more for a full AI-powered oncology platform

What Is AI Oncology Software?

AI oncology software is a technology platform that uses artificial intelligence, including natural language processing, machine learning, and clinical decision support, to support the diagnosis, treatment planning, coordination, and monitoring of patients with cancer across the full care pathway.

Oncology generates uniquely complex data. A single patient may have pathology reports describing histology and margins, molecular and genomic profiles listing dozens of variants, staging information from imaging, regimen details with cycle-by-cycle dose modifications, laboratory trends tracking toxicity, and patient-reported symptoms. Much of this information lives in unstructured text and external PDFs rather than structured fields, so general-purpose EHRs capture it poorly.

Traditional oncology information systems manage orders, scheduling, and regimen documentation. They do not read a pathology report and extract the biomarker status that determines eligibility for a targeted therapy, and they do not compare a patient's profile against hundreds of open trials. AI oncology software adds this intelligence layer, transforming scattered clinical information into structured, actionable insight at the point of decision.

Why Is AI Transforming Oncology in 2026?

Why Is Oncology Data So Hard to Use?

Most clinically decisive oncology data is unstructured. Biomarker results arrive as scanned laboratory reports. Staging is described in narrative notes. Prior therapies are recorded in outside summaries. Manual abstraction by nurses and registrars is slow, expensive, and inconsistent. AI that reads these documents and produces structured, source-linked data turns weeks of chart review into minutes while keeping the original evidence one click away for verification.

How Is Precision Medicine Raising the Complexity?

Treatment selection increasingly depends on molecular profiling. New targeted therapies and immunotherapies are approved each year, each tied to specific biomarkers, and guidelines update frequently. No clinician can track every change across every cancer type. AI that keeps current with guidelines and approvals, and surfaces the options relevant to a specific patient's profile, helps ensure patients are not missed by therapies they qualify for.

Why Is Clinical Trial Enrollment So Low?

Trials are vital to progress, yet fewer than 5 percent of adult patients enroll. Eligibility criteria are lengthy and written in free text, trial listings change constantly, and coordinators screen patients manually. AI that parses eligibility criteria and matches them against structured patient data can identify candidates continuously, expanding access for patients and improving enrollment for research programs and sponsors.

What Workforce Pressures Are Driving Adoption?

Oncology nurses, navigators, tumor registrars, and oncologists face growing caseloads and documentation burden. Time to treatment matters, and administrative delay is a modifiable cause. Automating abstraction, scheduling coordination, and monitoring frees staff for the human work of cancer care.

What Are the Key Use Cases for AI Oncology Software?

NLP Extraction From Pathology, Genomic, and Clinical Documents

AI reads pathology reports, molecular test results, radiology reports, and clinic notes to extract cancer type, histology, grade, stage, biomarker status, prior therapies, and treatment response into structured fields. Each extracted value links back to its source text so clinicians and registrars can verify it quickly. This structured foundation powers every other capability, from trial matching to quality reporting and tumor registry submission.

Our AI and ML solutions team builds clinical NLP models trained on oncology documentation, with the entity recognition accuracy and source traceability that safe abstraction requires.

Clinical Trial Matching

AI parses trial eligibility criteria and compares them against each patient's structured data, flagging likely matches and showing which criteria are met, unmet, or unknown. Coordinators receive a prioritized list instead of screening every patient against every trial manually. Because patient data changes over time, continuous re-matching surfaces new eligibility when a biomarker result arrives or a line of therapy fails.

Treatment Guideline Support

AI maps a patient's disease characteristics to current guideline pathways such as NCCN-style recommendations, presenting concordant options and relevant evidence for clinician consideration. The tool supports rather than dictates: the oncologist reviews, selects, and documents the plan. Because recommendation features may carry regulatory implications, intended use must be defined carefully from the start.

Tumor Board Preparation and Workflow

Tumor boards require assembling case summaries, imaging, pathology, and genomics for multidisciplinary review. AI generates concise case summaries from the structured record, highlights open questions, tracks which cases are scheduled and which materials are missing, and documents board recommendations back into the chart. Coordinators spend less time chasing records, and boards review better-prepared cases.

Our EHR and EMR integration practice builds the integrations that give oncology AI access to pathology, radiology, laboratory, and clinical documentation across systems.

Symptom and Toxicity Monitoring During Treatment

Chemotherapy and immunotherapy cause side effects that can escalate quickly. AI-supported patient-reported outcome programs collect symptoms between visits, combine them with laboratory trends, and flag patients at risk of serious toxicity, febrile neutropenia, dehydration, or immune-related events so nurses can intervene early. Early intervention reduces emergency visits and unplanned admissions.

Cancer patients move between surgery, radiation, medical oncology, imaging, and supportive care. AI tracks each patient's position in their pathway, flags overdue steps, such as a delayed referral or missed scan, and prompts navigators to act. Reducing the interval between diagnosis and treatment start is a direct quality improvement.

Oncology Practice Analytics and Quality Reporting

AI supports registry abstraction, quality measure reporting such as ASCO QOPI measures, drug utilization and cost analytics, and pathway adherence tracking. For value-based programs such as the Oncology Care Model successors, analytics that link treatment patterns to cost and outcomes help practices manage performance.

Our healthcare UI/UX design team designs oncology dashboards tested with oncologists, nurses, and navigators so insights are usable inside a busy clinic day.

What Are the Key Features of AI Oncology Software?

Unified Oncology Patient Record

A single longitudinal view combining diagnosis, staging, biomarkers, genomics, imaging, treatment history, and toxicity data, with source links for every extracted element.

Document Abstraction Engine

NLP pipelines that process pathology, molecular, radiology, and clinical documents, including scanned PDFs through OCR, with confidence scoring and a human review queue for low-confidence extractions.

Trial Matching Module

Eligibility criteria parsing, continuous patient re-matching, criterion-level explanations, and coordinator workflow tools for screening and referral.

Treatment Decision Support

Guideline-concordant option display with evidence references, biomarker-linked therapy indicators, and drug interaction checks against the patient's current medications.

Tumor Board Workspace

Case submission, auto-generated summaries, scheduling, material tracking, and documentation of consensus recommendations.

Patient Monitoring and Engagement

Mobile symptom reporting, toxicity alerts for nursing triage, appointment and treatment reminders, and education content tailored to regimen and cancer type. Our healthcare mobile app development team builds patient apps tested with patients undergoing treatment, who may be fatigued, anxious, or older.

Integration Layer

Connections to EHRs, laboratory and genomic vendors, PACS, and oncology information systems through HL7 FHIR, HL7 v2, and vendor APIs. Our API integration services team builds these connections, including mCODE-aligned data models for oncology interoperability.

HIPAA-Compliant Data Architecture

Encryption, role-based access, audit logging, and BAAs, plus enhanced protection for genomic data. Our HIPAA-compliant software development practice builds architecture suited to sensitive cancer and genomic records.

Analytics and Reporting

Registry and quality reporting, pathway adherence, trial enrollment metrics, and operational dashboards for oncology leadership.

How to Build AI Oncology Software: Step by Step

Step 1: Define Clinical Scope

Choose a focus: a specific tumor type, a function such as trial matching or abstraction, or a care setting such as community practice or academic center. Oncology is too broad to build everywhere at once. A focused scope that delivers clear value, such as structured abstraction for lung cancer biomarkers, is the right starting point.

Step 2: Determine FDA Regulatory Classification

Tools that analyze images or pathology to detect cancer, or that recommend specific therapies, may be regulated as Software as a Medical Device. Tools that extract and organize information, match trials, and coordinate workflow are more likely to fall within clinical decision support exemptions when clinicians can independently review the basis for outputs. Obtain regulatory counsel input before development. Our MVP and product strategy process includes this assessment in discovery.

Step 3: Map Data Sources and Integration

Identify EHRs, pathology and laboratory systems, genomic vendors, imaging systems, and tumor registries. Define data formats, access methods, and update frequency. Genomic reports from outside vendors often arrive as PDFs, so plan for OCR and format variability.

Step 4: Run a Discovery Sprint

Validate architecture, integrations, compliance, and AI approach before committing engineering resources. Discovery is where scope, regulatory position, and data realities are settled cheaply rather than expensively.

Step 5: Build the Ingestion and Abstraction Pipeline

Build document ingestion, OCR, and NLP extraction with source linking and confidence scoring. Validate extraction accuracy against registrar-labeled samples for each document type before building dependent features.

Step 6: Build the Structured Data Model

Model cancer data using standards such as mCODE and FHIR so that downstream features, from trial matching to analytics, operate on consistent, interoperable structures.

Step 7: Develop Trial Matching

Implement eligibility criteria parsing, criterion-level matching with met, unmet, and unknown states, and continuous re-matching as new data arrives. Validate precision and recall against coordinator-reviewed matches.

Step 8: Build Decision Support and Tumor Board Tools

Integrate guideline content from licensed or authoritative sources with clear versioning, and build tumor board workflows that generate summaries and track materials.

Step 9: Build Monitoring and Patient Applications

Develop symptom reporting, toxicity risk flagging, and nurse triage workflows with clinically validated escalation thresholds defined with oncology nursing leaders.

Step 10: Implement HIPAA Compliance Architecture

Apply encryption, access controls, and audit logging, with enhanced controls for genomic data and BAAs for every vendor, including messaging and genomic data partners.

Step 11: Pilot and Measure

Measure abstraction time saved, extraction accuracy, trial screening throughput and enrollment, time from diagnosis to treatment, toxicity-related emergency visits, and user satisfaction. Refine before scaling.

Our DevOps and cloud solutions team builds the deployment, monitoring, and data pipeline reliability that keeps the platform accurate as guidelines, trials, and models evolve.

What Technology Powers AI Oncology Software?

AI and Machine Learning

Python is the standard language. Clinical NLP uses fine-tuned transformer models such as BioBERT and ClinicalBERT, along with oncology-specific entity recognition for histology, stage, biomarkers, and therapies. OCR services such as Amazon Textract handle scanned reports. Large language model APIs can assist with summarization and criteria parsing when paired with retrieval from validated sources, structured output constraints, and mandatory source citation to reduce hallucination risk.

For toxicity and deterioration prediction, gradient boosting models trained on laboratory trends and patient-reported symptoms provide calibrated risk scores with SHAP explanations. Trial matching combines rule-based logic for structured criteria with NLP for free-text criteria.

Data Standards and Integration

HL7 FHIR R4, mCODE implementation guide for cancer data, HL7 v2 for laboratory and ADT feeds, DICOM for imaging, and SMART on FHIR for EHR-embedded launch. Terminologies include SNOMED CT, LOINC, ICD-O-3, RxNorm, and HGVS for genomic variants. ClinicalTrials.gov data supports trial listings.

Backend Infrastructure

Python with FastAPI, PostgreSQL for structured data, a document store for source files, Redis for queues, and AWS SQS for asynchronous processing. Search infrastructure such as Elasticsearch supports trial and document retrieval.

Patient Communication

HIPAA-eligible SMS, push, and email providers under BAAs, with careful minimization of sensitive detail in message bodies.

Cloud Infrastructure

AWS with a HIPAA BAA, including Amazon RDS, S3 with server-side encryption, SageMaker, Comprehend Medical, KMS, and CloudTrail for audit logging.

What Are the HIPAA Compliance Requirements for Oncology Software?

Oncology records are among the most sensitive in healthcare, and genomic data raises the stakes further.

What Technical Safeguards Apply?

AES-256 encryption at rest, TLS 1.2 or higher in transit, role-based access control separating oncologists, nurses, navigators, registrars, and research staff, multi-factor authentication for clinical users, session timeout, and comprehensive audit logging of record access.

Why Is Genomic Data Special?

Genomic data can identify an individual and reveal information about biological relatives. The Genetic Information Nondiscrimination Act provides protections in health insurance and employment, and some states add further rules. Apply stricter access controls, limit secondary use, and document consent for any research use.

How Should Research Use Be Handled?

Using patient data for trial matching outreach, research, or model training requires appropriate authorization, IRB involvement where applicable, or de-identification meeting HIPAA standards. Design data governance to separate treatment use from research use.

What About Patient Communications?

Messages that reference a cancer diagnosis or treatment are PHI. Use BAA-covered vendors, minimize content in message bodies, and honor patient preferences about who may be contacted.

How Much Does AI Oncology Software Cost to Build?

A focused MVP, covering document abstraction for one or two cancer types, a structured patient summary, and EHR integration, typically costs $60,000 to $130,000 and takes three to six months.

A mid-level platform, with broader abstraction, clinical trial matching, tumor board workflow, symptom monitoring, and multi-source integration, typically costs $130,000 to $320,000 and takes six to twelve months.

A full enterprise platform, with multi-cancer coverage, genomic data integration, guideline decision support, registry and quality reporting, patient monitoring app, multi-site deployment, and regulatory preparation where applicable, typically costs $320,000 to $520,000 or more and takes twelve to twenty-four months.

Annual maintenance, covering guideline and trial content updates, model retraining, integration upkeep, and compliance, typically runs $45,000 to $110,000.

What Are the Common Mistakes to Avoid When Building Oncology Software?

1. Trying to Cover Every Cancer Type at Once

Oncology is dozens of diseases with distinct data elements and pathways. Platforms that attempt universal coverage on day one deliver shallow value everywhere. Start with a defined tumor type or function and expand.

2. Extraction Without Source Traceability

Abstracted values that cannot be traced to the original text erode clinician trust. Every extracted element should link to its source passage, with confidence scores and a review queue for uncertain items.

3. Treating Trial Matching as a One-Time Screen

Eligibility changes as biomarkers return and treatments progress. Matching must run continuously, and it should show criterion-level reasoning, including unknowns, so coordinators know what to verify.

4. Using Generative AI Without Guardrails for Treatment Content

Fluent but incorrect treatment statements are dangerous. Ground outputs in curated guidelines and validated sources, require citations, and keep clinicians as the decision makers.

5. Ignoring Genomic Data Governance

Genomic data carries special privacy risk. Failing to plan for enhanced access controls, consent, and research governance creates legal and trust problems later.

6. Skipping Regulatory Classification

Image analysis for cancer detection and treatment-recommending features can trigger FDA oversight. Classify intended use before building.

How Does Codieshub Build AI Oncology Software?

At Codieshub, we build AI oncology software for cancer centers, community oncology practices, health systems, and health tech companies that need platforms designed for the complexity of cancer care, with traceable AI, rigorous privacy protection, and clinician-centered workflows.

Every engagement begins with our MVP and product strategy process, covering clinical scope, FDA classification assessment, data source and integration mapping, genomic data governance, HIPAA architecture, and workflow co-design with oncology teams before production code is written.

Our AI and ML solutions team builds oncology NLP abstraction, trial matching, toxicity risk models, and guardrailed summarization, with accuracy monitoring built in. Our EHR and EMR integration and API integration services teams connect EHRs, laboratories, genomic vendors, and imaging systems. Our healthcare mobile app development and healthcare UI/UX design teams create patient and clinician experiences tested with real users. Our HIPAA-compliant software development practice protects sensitive cancer and genomic data, and our DevOps and cloud solutions team keeps the platform dependable and current.

Conclusion

Cancer care asks clinicians to synthesize more information, under more time pressure, with higher stakes than almost any other field. The information exists, but it is scattered across documents and systems, and the effort of assembling it delays decisions and narrows patients' options.

AI oncology software changes that equation. It reads the documents, builds the unified picture, surfaces the trials and options a patient may qualify for, prepares the tumor board, and watches for toxicity between visits, all while keeping the clinician in command and the evidence traceable.

The organizations that deploy it well in 2026 will move patients to treatment faster, enroll more patients in trials, and give their oncology teams time to focus on what only humans can provide.

At Codieshub, we build AI oncology software for teams who understand what cancer care demands: accuracy, traceability, privacy, and respect for the clinicians and patients at the center.

Ready to build AI oncology software that accelerates treatment decisions and expands patient access? Schedule a Discovery Call. Tell us about your clinical focus and care setting, and we will send you a tailored development and compliance game plan within 48 hours.

Frequently Asked Questions

1. What is AI oncology software?

AI oncology software uses NLP, machine learning, and decision support to unify cancer patient data, extract structured information from pathology and genomic reports, support guideline-concordant treatment planning, match patients to clinical trials, prepare tumor boards, and monitor patients during treatment.

2. How does AI help with clinical trial matching?

AI parses free-text eligibility criteria and compares them with each patient's structured data, flagging likely matches and showing which criteria are met, unmet, or unknown. Continuous re-matching surfaces new eligibility as biomarkers and treatment status change, reducing manual screening burden.

3. Does oncology software need to be HIPAA compliant?

Yes. Cancer diagnoses, treatment records, and genomic data are protected health information. HIPAA requires encryption, role-based access, audit logging, and Business Associate Agreements. Genomic data warrants enhanced protections and GINA considerations.

4. How does AI extract data from pathology and genomic reports?

Clinical NLP models, combined with OCR for scanned documents, identify cancer type, histology, grade, stage, and biomarker results and convert them into structured fields. Each value links to its source text with a confidence score so staff can verify it quickly.

5. Does AI oncology software require FDA clearance?

It depends on intended use. Tools that detect cancer from images or recommend specific therapies may be regulated as Software as a Medical Device. Tools that organize information, match trials, and support workflow may qualify for clinical decision support exemptions. Regulatory review before development is essential.

6. How does AI support tumor boards?

AI generates case summaries from the structured record, highlights open questions, tracks scheduling and missing materials, and documents board recommendations in the chart. This reduces coordinator workload and helps boards review better-prepared cases.

7. How long does it take to build AI oncology software?

A focused MVP takes three to six months. A mid-level platform with trial matching and tumor board tools takes six to twelve months. A full enterprise platform takes twelve to twenty-four months. Integration complexity, extraction validation, and regulatory work are the main timeline drivers.

8. How much does AI oncology software cost to build?

A focused MVP costs $60,000 to $130,000. A mid-level platform costs $130,000 to $320,000. A full enterprise platform costs $320,000 to $520,000 or more. Annual maintenance typically costs $45,000 to $110,000. Key cost drivers are NLP development, integration breadth, genomic data handling, validation, and compliance.